Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

Pratteln, Switzerland, March 29, 2022– Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news